Toxicology and clinical potential of nanoparticles

We review current toxicity studies of NPs with clinical potential

Lara Yildirimer


Scholarcy highlights

  • The small particle size coupled to their unique chemical and physical properties is thought to underlie their exploitable biomedical activities
  • Mechanisms of cytotoxicity are discussed and the problem of extrapolating knowledge gained from cell-based studies into a human scenario is highlighted
  • The so-called ‘proof-of-principle’ approach, whereby ultra-high NP concentrations are used to ensure cytotoxicity, is evaluated on the basis of two considerations; firstly, from a scientific perspective, the concentrations used are in no way related to the actual doses required which, in many instances, discourages further vital investigations
  • In January 2009, she was appointed a University College London-RI Readership in Nanotechnology and based at The Davy Faraday Research Laboratory, The Royal Institution of Great Britain, the oldest independent scientific research body in the world. There she leads a very dynamic research team focused on the design, synthesis and study of the physical properties of nanomaterials as well as their applications in biomedicine
  • He has completed his education at University of London and University College London Medical School. He is a Fellow of the Institute of Nanotechnology and has published over 325 peer-reviewed research papers, 31 book chapters and 4 families of patents. He has led and managed many large projects with multidisciplinary teams with very successful outcomes in terms of commercialisation and translation to patients, including the development and commercialisation of a bypass graft for vascular access for haemodialysis; laser activated vascular sealants, regeneration of lacrimal ducts in man with Swiss eye surgeon Dr Karla Chaloupka using nanomaterials and stem cells and recently, the development of the first synthetic trachea based on a nanocomposite polymer and stem cells which has been implanted into a patient at the Karolinska Institute, Sweden
  • The discrepancies between in vitro and in vivo results are described along with the need for a unifying protocol for reliable and realistic toxicity reports

Need more features? Save interactive summary cards to your Scholarcy Library.